OBJECTIVE: Background tumor growth results in the mobilization of immune inhibitory CD34+ progenitor cells. However, vitamin D3 can differentiate the CD34+ cells into immune stimulatory dendritic cells. This study determined if docetaxel treatment could increase the impact of the vitamin D3 to generate dendritic cells.
METHODS: The murine squamous cell carcinoma model, SCC VII/SF, which is often used as a head and neck cancer model, was used to determine the immunological effects of two cycles of docetaxel plus vitamin D3.
RESULTS: Vitamin D3 with or without docetaxel was similarly effective in reducing CD34+ cell levels within the spleen, lymph nodes, and tumor. Dendritic cell levels were similarly enhanced in the lymph nodes by vitamin D3 alone or combined with docetaxel. However, the combination treatment caused a prominent increase in intratumoral levels of active T cells, which was not observed by the individual treatments.
BenvenutiFLagaudriere-GesbertCGrandjeanIDendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes. J Immunol2004; 172: 292–301.
2.
FerlazzoGWesaAWeiW-ZDendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol1999; 163: 3597–604.
3.
De PaolaFRidolfiRRiccobonARestored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br J Cancer2003; 88: 320–6.
4.
YoungMRLathersDM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol1999; 21: 241–52.
5.
ShibuyaTYWeiWZZormeierMAnti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg2000; 126: 473–9.
6.
HeimdalJHAarstadHJKlementsenBPeripheral blood mono-nuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis. Acta Otolaryngol1999; 119: 281–4.
7.
ChandlerSWRassekhCHRodmanSMImmunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas. Laryngoscope2002; 112: 808–15.
8.
JaviaLRRosenbergSA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother2003; 26: 85–93.
9.
YoungMRISchmidt-PakAWrightMAMechanisms of immune suppression in patients with head and neck cancer: Presence of immune suppressive CD34+ cells in cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res1995; 1: 95–103.
10.
PanditRLathersDMBealNMCD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol2000; 109: 749–54.
11.
YoungMRIWrightMAMatthewsJPSuppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J Immunol1996; 156: 1916–22.
12.
LathersDMRAchilleNKolesiakKIncreased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck cancer and the ability of the CD34+ cells to differentiate into antigen presenting dendritic cells. Clin Cancer Res2001; 125: 205–12.
13.
PalmerHGSanchez-CarbayoMOrdonez-MoranPGenetic signatures of differentiation induced by 1α,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res2003; 63: 7799–806.
14.
ElstnerELinker-IsraeliMSaidJ20-epi-vitamin D3 analogues: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res1995; 55: 2822–30.
15.
DuitsAJDimjatiWvan de WinkelJGJSynergism of interleukin 6 and 1α,25-dihydroxyvitamin D3 in induction of myeloid differentiation of human leukemic cell lines. J Leukoc Biol1992; 51: 237–43.
16.
GarrityTPanditRWrightMAIncreased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into CD1a+ cells. Int J Cancer1997; 73: 663–9.
17.
LathersDMClarkJIAchilleNJPhase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother2004; 53: 422–30.
18.
TsavarisNKosmasCVadiakaMImmune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer2002; 87: 21–7.
19.
FuKKRaynerPALamKN. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys1984; 10: 1473–8.
20.
InoharaHInoueTAkahaniSConcurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study. Anticancer Res2004; 24: 4135–40.
21.
YoungMRIIhmJLozanoYTreating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immune suppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother1995; 41: 37–45.
